Chronic Kidney Disease Market Size

Chronic Kidney Disease Market Analysis

The chronic kidney disease market is expected to register a CAGR of 6.6% during the forecast period.

COVID-19 has impacted the growth of the chronic kidney disease market. The lockdown measures imposed by the government to avoid the spread of coronavirus among the population resulted in the shutting down of patient visits in hospitals, clinics, and dialysis centers which has impacted the lives of patients suffering from chronic kidney diseases. For instance, from an article published in Frontiers in Physiology in July 2021, it has been observed that the diagnosis of various kidney diseases was delayed during the COVID-19 pandemic as non-urgent tests and visits were postponed due to the closure of medical services during the lockdown. This has affected the histological examination for kidney diagnosis and hence impacted the demand for diagnostic tests and equipment during the pandemic.

Also, an article published in Kidney International in October 2020 stated that in India, a survey was conducted in 19 hospitals which showed that 2404 patients were admitted for regular dialysis after the lockdown as compared to 2517 patients before the lockdown. Thus, the decreased ability of the hospitals to provide lifesaving in-center hemodialysis has reduced the number of dialysis sessions per week which has affected the demand for dialysis equipment and medications. This has impacted the market growth. However, with released restrictions, resumed diagnosis and dialysis services, and increased patient visits, the studied market is expected to grow over the forecast period.

Factors such as increasing incidences of chronic kidney disease, technological advancements in diagnostic tests for kidney diseases, and the increasing need for early detection are promoting the market growth. The rising burden of chronic kidney diseases among the population is a key factor driving the market growth. For instance, as per the data published by the Australian Institute of Health and Welfare, in August 2022, about 17,700 deaths from chronic kidney diseases were reported in Australia, in 2020. In addition, as per the same source, 76% of these deaths had CKD reported as an associated cause of death. This is expected to increase the demand for effective diagnosis and treatment drugs, hence propelling market growth.

Additionally, as per the data published by the Australian Institute of Health and Welfare, in August 2022, it has been observed that in Aboriginal and Torres Strait Islanders 292 males and 677 females per 100,000 population, have chronic kidney diseases in 2021, respectively. As per the same source, Indigenous Australians were 4.6 times more likely to be diagnosed with chronic kidney disease as compared to their non-Indigenous counterparts. Thus, the rising burden of kidney disease among the population is expected to increase the demand for effective drugs and treatment options, propelling market growth.

Furthermore, emerging technologically advanced products and diagnostics tests to early detect chronic kidney disease among the population as well as rising government initiatives towards CKD are also expected to increase the market growth. For instance, in March 2022, Nova Biomedical launched a new tool, Nova Max Pro Creatinine/eGFR Meter System, to improve kidney care through kidney function screening and early detection of kidney disease in point-of-care settings outside the hospital. The system offers a simplified meter and creatinine biosensor to measure blood creatinine and calculates the estimated glomerular filtration rate (eGFR) from a tiny 1.2 microliter capillary fingerstick blood sample in just 30 seconds. Also, in February 2021, the National Kidney Foundation (NKF) launched the first-ever national registry for patients at all stages of kidney disease, the National Patient Network in the United States. It improves the lives of people with kidney disease by better informing research, clinical care, drug development, and health policy decisions, as well as giving kidney patients the tools they need to stay educated and healthy.

Moreover, the rising company activities in developing drugs and increasing product launches are also contributing to the market growth over the forecast period. For instance, in March 2022, Lupin launched Sevelamer Hydrochloride tablets used to treat hyperphosphatemia in patients with CKD in the United States market. Also, in March 2022, the DCGI approved Zydus Lifesciences for its NDA for Oxemia, a first-of-its-kind oral treatment in India for anemia associated with chronic kidney disease (CKD).

However, the use of generic products in some countries is likely to hinder the growth of the chronic kidney disease market over the forecast period.